Form 10-Q Karyopharm Therapeutics For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Karyopharm Therapeutics (KPTI) Files $200M Mixed Securities Shelf
November 8, 2016 8:56 AM ESTKaryopharm Therapeutics (Nasdaq: KPTI) filed a registration with the U.S. SEC to sell up to $200 million of mixed securities.
... MoreKaryopharm Therapeutics (KPTI) Tops Q3 EPS by 12c
November 7, 2016 4:28 PM ESTKaryopharm Therapeutics (NASDAQ: KPTI) reported Q3 EPS of ($0.69), $0.12 better than the analyst estimate of ($0.81).
For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.
... More